A commercial stage, pharmaceutical company delivering innovative speciality pharmaceuticals that address patients’ unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders.
Feraccru® / Accrufer®
Our lead product is a novel, stable, non-salt based oral therapy and is approved in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV.
We are currently selecting a commercial partner for the United States where the product will be marketed as Accrufer®.Read more